03 Profile
Vital Signsby Bridgehead
Hansard to 12 November 2026 · 31,484 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Rare diseases
Nikolay Nikolov: no photograph is held, so the sector leader plate is shown instead.
Sector leader
Nikolay Nikolov
Director, Office of Immunology and Inflammation, FDA Center for Drug Evaluation and Research
Sept 2026Oct 2026Nov 2026to date
1
Quoted in the press, across 1 topic since 7 Sept 2026
02 Quoted on · 1 of 29 topics
Nikolay Nikolov: key facts
- Kind of voice
- Sector leader
- Role
- Director, Office of Immunology and Inflammation, FDA Center for Drug Evaluation and Research
- Quoted on
- Rare diseases
- Press coverage
- Quoted in the press
- Most recently quoted
- 7 Sept 2026
04 On the record · press
What Nikolay Nikolov has said
By outlet · bar length shows relative volume
- pmlive.com
Where Nikolay Nikolov has been quoted
- FDA approves Priovant's Lisraya for dermatomyositispmlive.com · 7 Sept 2026
How we found the articles that name Nikolay Nikolov: we searched news for these terms.
- rare disease
- rare conditions
- orphan drugs
- genetic disorder
- cystic fibrosis
- motor neurone disease
- muscular dystrophy
- Huntington
Also searched with “rare disease” in each of 8 national papers. Every term for Rare diseases
Verbatim
“For too long, patients with dermatomyositis have faced a significant unmet need for effective treatments, often relying on therapies meant for other diseases. This approval is a meaningful step forward, giving patients and their healthcare providers an approved oral therapy proven to help manage this rare and debilitating disease.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 12 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.